XBiotech Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $0 | $4.0M | $18.4M |
| Cost of revenue | — | — | $0 | $651,000 | $5.8M |
| Gross profit | — | — | $0 | $3.4M | $12.6M |
| Research and development | $47.4M | $37.8M | $32.8M | $31.5M | $28.3M |
| Operating expenses | — | $42.5M | $37.5M | $37.8M | $37.7M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Pretax income | -$45.3M | -$38.6M | -$24.3M | -$33.6M | -$25.5M |
| Income tax expense | $235,000 | -$32,000 | $244,000 | -$688,000 | -$8.0M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M |
| Balance Sheet | |||||
| Cash and equivalents | $125.6M | $172.7M | $200.0M | $157.3M | $237.0M |
| Current assets | $127.0M | $174.6M | $201.7M | $219.8M | $246.9M |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Current liabilities | $7.9M | $15.1M | $6.1M | $4.1M | $3.5M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
| Stockholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Depreciation and amortization | $1.7M | $1.7M | $1.7M | $2.6M | $2.6M |
| Stock-based compensation | $3.6M | $1.8M | $3.3M | $5.1M | $4.5M |
| Capital expenditure | $289,000 | $1.3M | $362,000 | $585,000 | $3.5M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Dividends paid | — | — | — | $0 | $75.0M |
| Share repurchases | — | $0 | $14,000 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 30.5M · Free float 90.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.